[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 2093 Introduced in Senate (IS)]

<DOC>






118th CONGRESS
  1st Session
                                S. 2093

To establish a program at BARDA for developing medical countermeasures 
               for viral threats with pandemic potential.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             June 21, 2023

Ms. Baldwin (for herself and Mr. Tillis) introduced the following bill; 
     which was read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL


 
To establish a program at BARDA for developing medical countermeasures 
               for viral threats with pandemic potential.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Disease X Act of 2023''.

SEC. 2. MEDICAL COUNTERMEASURES FOR VIRAL THREATS WITH PANDEMIC 
              POTENTIAL.

    (a) In General.--Section 319L(c)(4) of the Public Health Service 
Act (42 U.S.C. 247d-7e(c)(4)) is amended--
            (1) in subparagraph (D)--
                    (A) in clause (ii), by striking ``; and'' and 
                inserting a semicolon;
                    (B) by redesignating clause (iii) as clause (v); 
                and
                    (C) by inserting after clause (ii) the following:
                            ``(iii) the identification and development 
                        of platform manufacturing technologies needed 
                        for advanced development and manufacturing of 
                        medical countermeasures for viral families 
                        which have significant potential to cause a 
                        pandemic;
                            ``(iv) advanced research and development of 
                        flexible medical countermeasures against 
                        priority respiratory virus families and other 
                        respiratory viral pathogens with a significant 
                        potential to cause a pandemic, with both 
                        pathogen-specific and pathogen-agnostic 
                        approaches; and''; and
            (2) in subparagraph (F)--
                    (A) in clause (ii), by striking ``; and'' at the 
                end and inserting a semicolon;
                    (B) in clause (iii), by striking the period and 
                inserting ``; and''; and
                    (C) by adding at the end the following:
                            ``(iv) priority virus families and other 
                        viral pathogens with a significant potential to 
                        cause a pandemic.''.
    (b) Funding.--Section 319L(d)(2) of the Public Health Service Act 
(42 U.S.C. 247d-7e(d)(2)) is amended--
            (1) by striking ``To carry out'' and inserting the 
        following:
                            ``(i) In general.--To carry out''; and
            (2) by adding at the end the following:
                            ``(ii) Additional funding.--
                                    ``(I) In general.--In addition to 
                                the amounts appropriated under clause 
                                (i), there is authorized to be 
                                appropriated to the Fund $40,000,000 
                                for each of fiscal years 2024 through 
                                2028, which amounts shall be used 
                                solely for purposes of carrying out 
                                clauses (iii) and (iv) of subsection 
                                (c)(4)(D), such amounts to remain 
                                available until expended.
                                    ``(II) Restriction on use of 
                                funds.--Any product developed using 
                                funding appropriated pursuant to 
                                subclause (I) shall be substantially 
                                manufactured in the United States. The 
                                Secretary may waive the requirements of 
                                this subclause with respect to 
                                individual entities if the Secretary 
                                determines that requiring domestic 
                                research and development operations 
                                would be inconsistent with the public 
                                interest.''.
                                 <all>